Transforming growth factor beta 1 as a biomarker of diabetic peripheral neuropathy: Cross-sectional study

Journal of Diabetes and its Complications

Volumn 24, Issue 5, 2010, Pages 306-312

  Ybarra, Juan ^a   Pou, Josep M ^b   Romeo, June Hart ^c   Merce, Javier ^b   Jurado, Jeroni ^d  

^a CENTRO MÉDICO TEKNON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c BALDWIN WALLACE COLLEGE   (United States)

^d Catalan Health Institute   (Spain)

Author keywords

Diabetic peripheral neuropathy; TGF 1

Indexed keywords

BIOLOGICAL MARKER; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NEUROPHYSIOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SCREENING; SENSITIVITY AND SPECIFICITY;

EID: 77956229136     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2009.07.007     Document Type: Article

References (41)

1. Agrawal R.P., Sharma P., Pal M., Kochar A., and Kochar D.K. Magnitude of dyslipedemia and its association with micro and macro vascular complications in type 2 diabetes: A hospital based study from Bikaner (Northwest India) Diabetes Research and Clinical Practice 73 2006 211 214
2. Anjaneyulu M., Berent-Spillson A., Inoue T., Choi J., Cherian K., and Russell J.W. Transforming growth factor-beta induces cellular injury in experimental diabetic neuropathy Experimental Neurology 211 2008 469 479
3. Benbow S.J., Wallymahmed M.E., and Macfarlane I.A. Diabetic peripheral neuropathy and quality of life Quarterly Journal of Medicine 91 1998 733 737
4. Benjafield A.V., Glenn C.L., Wang X.L., Colagiuri S., and Morris B.J. TNFRSF1B in genetic predisposition to clinical neuropathy and effect on HDL cholesterol and glycosylated hemoglobin in type 2 diabetes Diabetes Care 24 2001 753 757
5. Blobe G.C., Schiemann W.P., and Lodish H.F. Role of transforming growth factor β in human disease New England Journal of Medicine 342 2000 1350 1358
6. Boulton A.J., Malik R.A., Arezzo J.C., and Sosenko J.M. Diabetic somatic neuropathies Diabetes Care 27 2004 1458 1486
7. Boulton A.J.M., Vileikyte L., Ragnarson-Tennvall G., and Apelqvist J. The global burden of diabetic foot disease Review Lancet 366 2005 1719 1724
8. Chantry D., Turner M., Abney E., and Feldmann M. Modulation of cytokine production by transforming growth factor-beta Journal of Immunology 142 1989 429 435
9. Cameron N.E., and Cotter M.A. Pro-inflammatory mechanisms in diabetic neuropathy: Focus on the nuclear factor kappa B pathway Current Drug Targets 9 2008 60 67
10. Delarue J., Maingourd C., Couet C., Vidal S., Bagros P., and Lamisse F. Effects of oral glucose on intermediary metabolism in continuous ambulatory peritoneal dialysis patients versus healthy subjects Peritoneal Dialysis International 18 1998 505 511
11. Dyck P.J., Kratz K.M., Lehman K.A., Karnes J.L., Melton L.J. III, O'Brien P.C., Litchy W.J., Windebank A.J., Smith B.E., and Low P.A. The Rochester Diabetic Neuropathy Study: Design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests Neurology 41 1991 799 807
12. Fukumoto H., Naito Z., Asano G., and Aramaki T. Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus Journal of Atherosclerosis and Thrombosis 5 1998 29 35
13. Gerstein H.C., Mann J.F., and Yi Q. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non diabetic individuals Journal of the American Medical Association 286 2001 421 426
14. Gruden G., Bruno G., Chaturvedi N., Burt D., Schalkwijk C., Pinach S., Stehouwer C.D., Witte D.R., Fuller J.H., and Perin P.C. Serum heat shock protein 27 and diabetes complications in the EURODIAB prospective complications study: A novel circulating marker for diabetic neuropathy Diabetes 57 7 2008 1966 1970
15. Hadi H.A., and Suwaidi J.A. Endothelial dysfunction in diabetes mellitus Vascular Health Risk Management 3 2007 853 876
16. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality for coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction New England Journal of Medicine 339 1998 229 234
17. Hong S.Y., and Yang D.H. Insulin levels and fibrinolytic activity in patients with end-stage renal disease Nephron 68 1994 329 333
18. Iwasaki T., Togashi Y., and Terauchi Y. Significant association of serum albumin with severity of retinopathy and neuropathy, in addition to that of nephropathy, in Japanese type 2 diabetic patients Endocrine Journal 55 2 2008 311 316
19. Jiang X., Kanai H., Shigehara T., Maezawa A., Yano S., and Naruse T. Metabolism of transforming growth factor-beta in patients receiving haemodialysis specially those with renal osteodystrophy Renal Failure 20 1988 135 145
20. Jurado J., Caula J., and Pou J.M. Selection of risk and diagnosis in DPN. Validation of method of new systems Atencion Primaria 38 2006 116 121
21. Jurado J., Ybarra J., Ferrandiz M., Comerma L., and Pou J.M. Is the aminoterminal pro-brain natriuretic peptide (NT-proBNP) a marker for DPN? Diabetes Care e86 2007 30
22. Jurado J., Ybarra J., Romeo J.H., and Pou J. Clinical screening and diagnosis of diabetic polyneuropathy: The North Catalonia Diabetes Study European Journal of Clinical Investigation 39 3 2009 183 189
23. 1.induced glomerular disorders is associated with impaired concentrating ability mimicking primary glomerular disease with renal failure in men Laboratory Investigation 80 2000 1855 1958
24. Mi Q., Rivière B., Clermont G., Steed D.L., and Vodovotz Y. Agent-based model of inflammation and wound healing: Insights into diabetic foot ulcer pathology and the role of transforming growth factor-beta1 Wound Repair and Regeneration 15 2007 671 682
25. Navarro J.F., and Mora C. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy Scientific World Journal 6 2006 908 917
26. Nikol S., Isner J.M., Pickering J.G., Kearney M., Leclerc G., and Weir L. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions Journal of Clinical Investigation 90 1992 1582 1592
27. Partanen J., Niskanen L., Lehtinen J., Mervaala E., Siitonen O., and Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus New England Journal of Medicine 333 1995 89 94
28. Pedersen O., and Gaede P. Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: The Steno-2 study Metabolism 52 2003 19 23
29. Quattrini C., Tavakoli M., Jeziorska M., Kallinikos P., Tesfaye S., Finnigan J., Marshall A., Boulton A.J., Efron N., and Malik R.A. Surrogate markers of small fiber damage in human diabetic neuropathy Diabetes 56 8 2007 2148 2154
30. Reeves W.P., and Androly T.E. Transforming growth factor a contributes to progressive diabetic nephropathy Proceedings of the National Academy of Sciences of the United States of America 97 2000 7667 7669
31. Roberts R.A., Michel C., Coyle B., Freathy C., Cain K., and Boitier E. Regulation of apoptosis by peroxisome proliferators Toxicology Letters 149 2004 37 41
32. Rubino A., Rousculp M.D., Davis K., Wang J., Bastyr E.J., and Tesfaye S. Diagnosis of diabetic peripheral neuropathy among patients with type 1 and type 2 diabetes in France, Italy, Spain, and the United Kingdom Primary Care Diabetes 1 3 2007 129 134
33. Sandhu H.S., Butt A.N., Powrie J., and Swaminathan R. Measurement of circulating neuron-specific enolase mRNA in diabetes mellitus Annals of the New York Academy of Sciences 1137 2008 258 263
34. Schneider C.A. Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control Current Medical Research and Opinion 22 Suppl. 2 2006 S15 S26
35. Shlipak M.G., Ix J.H., Bibbins-Domingo K., Lin F., and Whooley M.A. Biomarkers to predict recurrent cardiovascular disease: The Heart and Soul Study American Journal of Medicine 121 2008 50 57
36. Smith A.G., Russell J., Feldman E.L., Goldstein J., Peltier A., Smith S., Hamwi J., Pollari D., Bixby B., Howard J., and Singleton J.R. Lifestyle intervention for pre-diabetic neuropathy Diabetes Care 29 2006 1294 1299
37. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 1993 434 444
38. Tesfaye S., Chaturvedi N., Eaton S.E., Ward J.D., Manes C., Ionescu-Tirgoviste C., Witte D.R., Fuller J.H. for the EURODIAB Prospective Complications Study Group Vascular risk factors and diabetic neuropathy New England Journal of Medicine 352 2005 341 350
39. Tsuzura S., Ikeda Y., Suehiro T., Ota K., Osaki F., Arii K., Kumon Y., and Hashimoto K. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes Metabolism 53 2004 297 302
40. Turner R.C., Millns H., Neil H.A., Stratton I.M., Manley S.E., Matthews D.R., and Holman R.R. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS:23) British Medical Journal 316 1998 823 828
41. Vinik A.I., Maser R.E., Mitchell B.D., and Freeman R. Diabetic autonomic neuropathy Diabetes Care 26 2003 1553 1579